Oncogene-expressing human papillomavirus type 16 (HPV16) is found in a subset of head and neck squamous cell carcinomas (HNSCC). HPV16 drives carcinogenesis by inactivating p53 and pRb with the viral oncoproteins E6 and E7, paralleled by a low level of mutations in TP53 and allelic loss at 3p, 9p, and 17p, genetic changes frequently found in HNSCCs of nonviral etiology. We hypothesize that two pathways to HNSCC exist: one determined by HPV16 and the other by environmental carcinogens. To define the critical genetic events in these two pathways, we now present a detailed genome analysis of HNSCC with and without HPV16 involvement by employing high-resolution microarray comparative genomic hybridization. Four regions showed alterations in HPV-negative tumors that were absent in HPV-positive tumors: losses at 3p11.2-26.3, 5q11.2-35.2, and 9p21.1-24, and gains/amplifications at 11q12.1-13.4. Also, HPV16-negative tumors demonstrated loss at 18q12.1-23, in contrast to gain in HPV16-positive tumors. Seven regions were altered at high frequency (>33%) in both groups: gains at 3q22.2-qter, 5p15.2-pter, 8p11.2-qter, 9q22-34.1, and 20p-20q, and losses at 11q14.1-qter and 13q11-33. These data show that HNSCC arising by environmental carcinogens are characterized by genetic alterations that differ from those observed in HPV16-induced HNSCC, and most likely occur early in carcinogenesis. A number of genetic changes are shared in both tumor groups and can be considered crucial in the later stages of HNSCC progression.
Introduction
Head and neck squamous cell carcinoma (HNSCC) comprises about 5% of all newly diagnosed cancer cases in the Northern and Western European countries and the United States, and is the fifth most common cancer worldwide (Pisani et al., 2002) . Despite advances in local tumor control, the 5-year survival rates of approximately 50% have only moderately improved during the last 20 years, and identification of the cancer genes causally involved in carcinogenesis seems crucial to enable development of new therapeutic agents aimed at improving survival. HNSCC arises by the accumulation of genetic and epigenetic changes in oncogenes, tumor suppressor genes, and/or DNA stability genes (Vogelstein and Kinzler, 2004) . Using cytogenetics, loss of heterozygosity (LOH) analysis, and comparative genomic hybridization (CGH), over 20 recurrent chromosomal alterations have been found in invasive HNSCCs, including losses at 3p, 9p, and 17p, and gains at 3q26 and 11q13 (Bockmuhl et al., 2000; Gollin, 2001; Beder et al., 2003; Tsao et al., 2004; Wreesmann et al., 2004) . The relatively high frequency of these chromosomal aberrations, which occur usually in over 30% of carcinomas, or the association with prognosis argues for a role in head and neck carcinogenesis.
HNSCC arises by a chemical etiology encompassing well-established causative life-style-related agents, like tobacco smoking and alcohol abuse. Recently, the role of the human papillomavirus (HPV) in head and neck carcinogenesis as a separate etiologic factor has been firmly established (Gillison et al., 2000; Dahlgren et al., 2003; Braakhuis et al., 2004a) . Human papillomaviruses are epitheliotropic DNA viruses with a genome of approximately 8 kb. More than 100 subtypes are distinguished at present, and some subtypes have been assigned as high-risk types, as they are the main causative factors in the development of cervical cancer (Zur Hausen, 2002) . The virus produces two oncoproteins, encoded by the E6 and E7 genes, that inactivate the p53 and pRb proteins, respectively, providing cell cycle entry and DNA synthesis needed for viral replication. It was recently shown that tumors containing oncogene-expressing HPV are genetically different from those that do not contain HPV, and arose most likely as a result of exposure to environmental carcinogens. Tumors with oncogene-expressing HPV (in particular HPV16) did not show any TP53 mutation and very limited allelic losses at 3p, 9p, and 17p, while in 75% of tumors not containing HPV a TP53 mutation had occurred and very frequent allelic loss was found (Braakhuis et al., 2004b) . These results suggest that an infection with HPV is an early event in HNSCC development that persists throughout the entire period of cancer progression. Moreover, the disruption of the pRb and p53 pathways by the viral oncoproteins is reflected in a unique genotype of tumors with oncogeneexpressing HPV.
These two different genetic pathways caused by chemical carcinogens and HPV leading to one single tumor type form a unique opportunity to detect the relevant genetic events in head and neck cancer. We now present for the first time a detailed and comprehensive genetic analysis of HNSCCs of different etiology. With a genome-wide high-resolution method, we determined the chromosomal regions that show different alterations between tumors with and without oncogene-expressing HPV, and those that are shared, and combined the data to propose an integrated HNSCC progression model.
Results

CGH profiles of HPV-positive and -negative tumors
In all, 12 tumors that were HPV DNA-positive with E6/E7 expression and 12 HPV-negative tumors were selected from a previously published cohort of 143 tumors that had been analysed for HPV and TP53 mutations (Braakhuis et al., 2004b) , and maCGH was carried out. The two groups of tumors did not differ statistically with regard to patient age at diagnosis or tumor site (Table 1 ). The consumption of alcohol and tobacco was also not different between the groups (details in Table 1 ).
The maCGH profiles were smoothed to define the regions that show copy number changes. The significance of the data was checked by calculating the 99% confidence interval on the log 2 ratios of nonaltered chromosomes for each sample. All values indicated as gain or loss by the smoothing algorithm exceeded the 99% confidence interval level, an indication of the reliability of the data set. The total number of BAC clones showing an alteration varied considerably between tumors: from 886 to 3969 clones for HPVnegative tumors, and from 256 to 2831 BAC clones for HPV-positive tumors. The frequency plot of alterations per BAC clone of chromosome 1-22 is shown in Figure 1 . On average, the HPV-positive tumors showed a significantly (P ¼ 0.04, normal scores two-sample rank test) lower total number of alterations, as compared with HPV-negative tumors, that is, 28 versus 44% of the BAC clones studied, respectively. One HPV-positive tumor showed a remarkably low number of copy number changes (alterations for only 256 BAC clones), showing only gain of a small region of 11q and an extra copy of chromosome 20.
Genetic alterations different between HPV-positive and -negative tumors We analysed the chromosomal regions that showed significant differences between the HPV-positive and -negative tumors. Significantly (Po0.05) differential genetic alterations were found in nine regions (Table 2) . Each significant chromosomal region consisted of spatially consecutive BAC clones and all regions encompassed in total 505 (12.6%) of the 3969 clones analysed. All significant regions spanned large parts of chromosomes or contained an entire chromosomal arm. The smallest different region just spanned four megabases and was located on chromosome 11q12.1-11q13.4. For some chromosomal regions the significance was based on a small number of tumors with opposite Genetic alterations in head and neck cancer SJ Smeets et al alterations. For example, the region 1p31.1-13.1 showed gains in two HPV-positive cases compared to losses in four cases of the HPV-negative group. In this example, the opposite value (À1 versus þ 1) of losses versus gains largely determined the significance. We therefore calculated the false discovery rate (FDR) on our data to adjust for multiple testing. FDR correction is likely to be conservative considering the relatively small number of cases, but several differentially altered regions at various chromosomes remained highly significant, as indicated by relatively low FDR values. The FDR value of 0.3 as for region 1p31.1-13.1 indicates that the relevance of this finding should be interpreted with caution, and we therefore focused particularly on the regions with P-values o0.05 and low FDR values.
Based on FDR correction, five chromosomal areas that displayed a very pronounced difference of alterations between the groups fulfilling the significance criterion were identified (Po0.05). Four of these chromosomal regions were altered in a relatively large number of HPV-negative tumors, while they were hardly changed in the HPV-positive group. First, loss of 3p11.2-26.3 was observed in more than 10 HPVnegative cases, whereas in HPV-positive cases once a gain and twice a loss was found. Region 5q11.2-35.2 was lost in eight cases of the HPV-negative group, whereas the 5q arm was lost in just one case and gained in one case in the HPV-positive group. In addition, loss of 9p24-9p21.1 was seen in six cases of the HPVnegative group, while this was not observed in the HPV-positive cases. The most striking observation was the gain or amplification of the 11q12.1-11q13.4 region in 10 cases of the HPV-negative group, while this gain was completely absent in the HPV-positive group. Furthermore, the difference of the region 18q12.1-18q23 was remarkable as it was lost in seven HPVnegative tumors and gained in five HPV-positive tumors (Table 2) .
Genetic alterations common HPV-positive and -negative tumors Besides differential changes between HPV-negative and -positive tumors, seven genomic regions also were found with a high frequency of common gains and losses.
Regions that showed common gains in more than four of 12 cases in each group were on chromosome arms 3q, 5p, 8p, 8q, 9q, 20p, and 20q ( Table 3 ). Regions that showed common chromosomal losses in more than four of 12 cases in each group were detected on chromosome arms 11q and 13q (Table 3) .
Discussion
The role of HPV as an important carcinogenic agent in a subset of HNSCCs has been well established at present. Very recently, Braakhuis et al. (2004b) suggested, based on the analysis of HPV status, TP53 mutation, and LOH, that two genetic routes of multi-step head and neck carcinogenesis exist. According to their hypothesis, the first and the most frequent route results from chemical carcinogen exposure, and is characterized by frequent TP53 mutations and allelic loss of large chromosomal regions at 3p, 9p, and 17p, which are considered early events in HNSCC development (Van der Riet et al., 1994; Califano et al., 1996; Mao et al., 1996; Partridge et al., 2000; Rosin et al., 2000; Tabor et al., 2003; Braakhuis et al., 2004a) . The second route is associated with active HPV infection and characterized by lack of TP53 mutations and a low level of allelic loss. These data were interpreted as proof for the concept that HPV16 is actively involved in the early steps of the development of a subgroup of HNSCC and that the virus remains active during the entire carcinogenic process (Braakhuis et al., 2004b; Mao and Hong, 2004) . We now show the common and differential genetic alterations between the two groups of tumors. Four chromosomal regions showed more alterations in HPV-negative tumors (either gains or losses) than in HPV-positive tumors (hardly any or no changes): loss at 3p11.2-26.3, 5q11.2-35.2, 9p21.1-24, and gain/amplification at 11q12.1-13.4. Since there is evidence that an active HPV infection occurs early in cervical and HNSCC carcinogenesis (Zur Hausen, 2002; Braakhuis et al., 2004b) , the genetic alterations that have been found presently in the HPV-negative tumors only are likely to reflect the early carcinogenesis. These alterations can be considered an alternative for the biological effects of the viral oncogenes E6 and E7. The frequent gain/amplification at 11q13 and the frequent loss at the region 9p21 in HPV-negative tumors, while showing no alteration in HPV-positive tumors, seem biologically plausible in this respect. The most likely candidate oncogene at the highly significantly amplified region 11q13 is CCND1 (Cyclin D1), a component of the CDK/Cyclin complex that phosphorylates pRb, causing S-phase entry. In addition, the region 9p21 encompasses the tumor suppressor gene CDKN2A (p16), an important inhibitor of the CDK/Cyclin complex preventing S-phase entry, that is often altered in HNSCC. In HPVinfected tumors the pRb pathway is disrupted by the oncoprotein E7, while apparently in HPV-negative tumors the pathway is impaired by mutation or loss of p16 and/or amplification of CCND1. In the present study, 5/12 tumors showed both loss at 9p21 and gain/ amplification at 11q13, suggesting that in some cases it seems necessary to alter two components of the pRb pathway to be at least functionally equivalent to pRb binding by HPV E7. This hypothesis needs to be proven by in vitro or mouse models.
In contrast to the biologically plausible findings concerning the pRb pathway, we did not observe a difference at a region we also expected to find, namely, the region 17p13, encompassing the tumor suppressor gene TP53. The viral oncogene E6 binds and inactivates p53, while in tumors without HPV involvement TP53 gene is mostly inactivated by mutation, often accompanied by allelic loss (Ahomadegbe et al., 1995; Erber et al., 1998; Tabor et al., 2001; Braakhuis et al., 2004b) . In a previous study, we showed that a significant difference in allelic loss frequency at 17p was observed between HPV-positive and -negative tumors, as determined by microsatellite markers (Braakhuis et al., 2004b) . In the HPV-negative tumors, HNSCC frequent TP53 mutations and allelic loss at 17p was found, while they were absent in the HPV-positive tumors. With maCGH we found frequent copy number gains at this locus in the HPV-negative group, while expecting copy number losses. This paradox can be explained by the fact that using microsatellite markers allelic imbalance is measured, as either gain or loss of an allele. In the present maCGH analysis, a mixture of gains and losses was observed in the HPV-negative tumors, making it impossible to detect the difference.
Some of the loci that show significant differences between HPV-positive and -negative tumors have been reported in other studies that focused on the identification of genetic events associated with prognosis of HNSCC. Loss of 3p and gain or amplification of 11q13 were previously identified by Bockmuhl et al. (2000) as (Gillison et al., 2000) . An intrinsic problem with these approaches, however, remains that genetic changes that are specifically linked to clinical failures may only reflect late progression and do not allow identification of chromosomal loci that play a role in the earlier phase of carcinogenesis. Moreover, the different outcomes, distant metastasis, locoregional recurrence as a result of residual cancer cells, or second-field tumors (Tabor et al., 2001 (Tabor et al., , 2004 , are very different biologically entities and are most likely associated with different genetic changes. The majority of loci presented here showed losses or gains in HPV-negative tumors and no apparent changes in HPV-positive tumors. There appeared to be one exception. Chromosomal region 18q12.1-23 was lost in seven of 12 (58%) HPV-negative tumors, but appeared to be gained in five of 12 (41%) HPV-positive tumors. SMAD4 has been proposed as a candidate cancer gene at 18q21.1, as deletion and mutation of this gene in a subset of HNSCC was observed (Hahn et al., 1996; Kim et al., 1996) . Whether this or another gene is involved in HPV-induced HNSCC remains to be determined.
Besides differences, both tumor groups were shown to share several altered regions. Gains at 3q22.2-qter, 5p15.2-pter, 8p11.2-8qter, 9q22-34.1, 20p-20q, and loss of 11q14.1-qter (telomeric from the 11q13 amplicon) and 13q11-33 were detected in often more than 50% of the tumors in both groups. These can be considered genetic changes that are important in head and neck carcinogenesis, as they frequently occur independent from the etiological factors causing these tumors. The question can be asked as to how these common alterations should be placed in the time-frame of HNSCC multistep carcinogenesis. The most likely option is that these common alterations occur late in progression.
The results of the present study are consistent with and provide further evidence for the hypothesis that HNSCCs develop by two different etiologies (Gillison et al., 2000; Van Houten et al., 2001; Herrero et al., 2003) : one driven by exposure to environmental carcinogens (i.e. tobacco and alcohol) without HPV Figure 2 A genetic progression model of multi-step head and neck carcinogenesis is proposed. The two etiological factors, smoking and HPV16, are incorporated into the 'patch-field-cancer' model that in essence has previously been published (Braakhuis et al., 2004a) . In this model, the development of a field with genetically altered cells plays a central role. In the initial phase a 'patch' develops, a clonal unit in which the stem cell and its daughter cells acquire a genetic alteration. Some evidence point to an alteration in the p53/ MDM2 pathway as a likely first event. This pathway is disrupted by a mutation of TP53 in case of smoking as a causative factor, or alternatively, by the HPV effect of E6, that results in a degradation of p53. The conversion of a patch into a field is the next step in this progression model, and this field expands at the expense of the normal epithelium. An important event in the field phase is the impairment of the p16/CDK/pRb pathway (Tabor et al., 2001) . In case of smoking, this pathway is disrupted by inactivating CDKN2A, the gene encoding p16, by mutation, chromosomal loss, or promoter hypermethylation. Alternatively, this pathway can be impaired by E7, a protein that is produced by HPV. Next, clonal divergence leads to the development of one or more tumors within the contiguous field of preneoplastic cells. Considering the two etiological factors, the common and differential chromosomal events possibly involved in the progression from field to carcinoma are shown. At this moment, it is difficult to point out the pathways that are involved in this stage of carcinogenesis. CCND1 (Cyclin D1) is likely involved in smoking-related HNSCC, since the 11q13 region is found to be highly significantly amplified; cyclin D1 is part of the p16/CDK/pRb pathway, a component of the CDK/Cyclin complex that phosphorylates pRb causing S-phase entry. involvement and the other involving infection with oncogene-expressing HPV16. However, we now also provide evidence that the two carcinogenic routes -one with HPV and the other without HPV involvementpartly overlap. As stated above, this finding may implicate that these common alterations are necessary events in HNSCC, irrespective of the etiological factor. It cannot be excluded, however, that the overlapping genetic events are related to the exposure to cigarette smoke. Most of our HPV-positive patients have smoked or are current smokers, making this group not different from the normal HNSCC patient population in that respect. Our present results show that although the two carcinogenic routes, virus and exposure to environmental carcinogens, differ in multiple ways, particularly related to the early genetic events and the activity of the known viral oncogenes E6 and E7, the late genetic events are common. The results of the present study indicate that to describe the development of HNSCC an integrated genetic progression model needs to be considered. This model presented in Figure 2 builds upon the previous existing models, but now includes the HPV route and the different and common genetic events (Califano et al. 1996; Braakhuis et al., 2004a) .
Materials and methods
Patients and tumor specimens
We obtained tumor specimens from 143 consecutive patients who underwent surgical treatment for a tumor in the head and neck region at the VU University Medical Center. Primary tumor samples were immediately snap-frozen in liquid nitrogen and stored at À801C. In 12 tumors HPV16 DNA and E6/ E7 mRNA expression was determined. This was considered to reflect direct viral involvement and was used as selection criterion for the case group (Braakhuis et al., 2004b) . The HPV-positive case group was compared with a HPV DNAnegative control group of 12 HNSCC, in part (10/12) similar to the group published previously (Braakhuis et al., 2004b) . Cases and controls were stratified according to tumor site (oral cavity or oropharynx), as well as degree of differentiation, and further selected in such a way that a similar distribution over the groups was ensured for those clinical parameters that might in theory confound the analysis (i.e., age, sex, smoking and drinking behavior, and TNM stage). The Fisher's exact test and w 2 test were used to assess the statistical significance of frequency distributions between case and control groups ( Table 1 ). The study was approved by the Institutional Review Board of the VU University Medical Center, and written informed consent was obtained from all patients.
Information on patient tobacco and alcohol use was obtained from the medical files. Patients were classified as never, former (at least one year of tobacco abstinence), or current daily tobacco smokers as well as never, former, or current alcohol drinkers.
Detection of high-risk HPV DNA and E6/E7 transcripts Frozen tumor samples were used for HPV analysis and for all tumor samples microdissection was performed to enrich for tumor tissue. DNA and RNA were extracted as described previously (Tabor et al., 2001) . Detection of the presence of HPV16 DNA and expression of the oncogenes E6 and E7 was performed as described previously (Braakhuis et al., 2004b) .
Microarray CGH
Arrays of Bacterial Artificial Chromosomes (BACs) were prepared from the 1 Mb resolution Sanger BAC set (http:// www.ensembl.org/Homo_sapiens/index.html) and the Onco-BAC set (http://informa.bio.caltech.edu/Bac_onc.html), and in-house clones of interest, supplemented with clones from the Children's Hospital Oakland Research Institute (CHORI), amounting to a total of 5659 clones with known chromosomal positions. DNA of BAC clones was isolated according to published protocols available on the web (http://bacpac.chori.org/dnaprep.htm).
Amplification of BAC clone DNA was performed by ligation-mediated polymerase chain reaction (PCR) according to Snijders et al. (2001) , followed by purification with Montage PCR s m96 filter plates (Millipore BV, Amsterdam, the Netherlands). This DNA was spotted at a concentration of 10 mg/ml in 150 mM sodium phosphate buffer, pH 8.5) on CodeLinkt microscopic glass slides (Amersham Bioscience, Roosendaal, The Netherlands), using a Spot Array 72 robot (Perkin-Elmer Life Sciences, Zaventum, Belgium). The printed glass slides were further processed according to the instructions of the manufacturer.
Test DNA, extracted as described previously (Tabor et al., 2001) , and reference genomic DNA isolated from randomized blood donors (300 ng of each) were labeled with a random primer elongation kit (Invitrogen, Breda, The Netherlands) in a 50 ml reaction with Cy3 dCTP and Cy5 dCTP (Perkin-Elmer Life Sciences). Nonincorporated nucleotides were removed using ProbeQuant G-50 Micro Columns (Amersham Biosciences). Labeled DNA was mixed with Cot-1 DNA (Invitrogen) and precipitated with ethanol. DNA was dissolved in 190 ml hybridization mix with a final composition of 50% formamide, 10% dextran sulphate, 2 Â SCC, 4% SDS, and 1.3 mg yeast tRNA. The hybridization solution was heated to 731C for 10-15 min to denature the DNA, and then incubated at 371C for 1 h to allow blocking of repetitive sequences. The array slides were prehybridized with a hybridization mix containing 650 mg salmon sperm DNA without probe at 371C in a hybridization station (Hybstation 12; Perkin-Elmer Life Sciences) for 1 h. Subsequently, slides were hybridized for 48 h at 371C. After hybridization, slides were washed six times in 50% formamide, 2 Â SCC, pH 7.0, at 451C, and twice in PN buffer (0.1 M sodium phosphate, 0.1% nonidet P40, pH 8.0) at room temperature, twice with 0.2 Â SCC and twice with 0.1 Â SCC. Slides were scanned with Scan Array Express (PerkinElmer Life Sciences).
Image acquisition and data analysis Image analysis was carried out with Imagenet software (BioDiscovery, El Segundo, CA, USA). Spots with nonhomogeneous fluorescence were automatically flagged and excluded from further analysis. Mean log 2 ratios of the triplicate Cy3 and Cy5 signals of each spot were calculated in a spreadsheet (Excel 2000, Microsoft Corp., Amsterdam, The Netherlands) after subtraction of the mean local background. BAC clones with a standard deviation above 0.2 over the triplicate values were excluded from further analysis. Normalization per array was carried out using the modus of the log 2 ratios of all unflagged clones. The clones were ordered by position in the genome according to the UCSC draft genome sequence ('freeze' July 2003; http://www.sanger.ac.uk). With a 'smoothing' algorithm, the gains (>0) and losses (o0) were defined over chromosome 1-22 on basis of the log 2 values (Jong et al., 2004) . The smoothing algorithm 'aCGH-Smooth' uses a heuristic algorithm, based on the assumption that the experimental noise in the data is generated by a Gaussian process. It identifies breakpoints and smoothens the observed array CGH values between consecutive breakpoints to a suitable common value. All log 2 ratios exceeding 1.0 were considered to indicate amplifications. Chromosome X-clones were discarded from further analysis, since all tumor samples were hybridized to reference DNA of the opposite gender. Only data of BACs were included in the analysis when at least 20/24 tumors showed a value. After the exclusion procedures, a total number of 3969 clones could eventually be analysed per array.
To perform this analysis, the 'smoothed'Àlog 2 ratios were converted to categorized data of ' þ 1' for chromosomal gains, 'À1' for chromosomal losses, and '0' if no change was determined. To identify the differential chromosomal loci between the two tumor groups, these smoothed data were used for the Wilcoxon rank sum test with ties, which was implemented in two web-based applications: 'CGHMultiArray' and 'CGHMultiArrayRegion' test (www.win.tue.nl/ markvdw/CGHMultiArray.html), especially developed for differential genetic analyses using CGH microarray data ( Van de Wiel et al., 2005) . Both tests take the discrete nature of the smoothed data into account. The first, 'CGHMultiArray', computes P-values per clone, and the second, 'CGHMultiArrayRegion' test, defines regions of adjacent and identical alterations, which are then considered as one testing entity. This reduces the multiplicity problem severely and allows adaptation of the usual Benjamini-Hochberg FDR type corrections. For more information, we refer to the supplementary information at http://webmathematica.win.tue.nl/ mark/cghregion/index.html. We noted that the analysis could be disturbed by opposite events that occurred only in a few tumors. These events can be considered accidental and therefore we also performed the statistical analysis by comparing two groups by adjusting either all gains or all losses to 'no change' (from ' þ 1' to '0' or from 'À1' to '0', respectively).
